Artiva Biotherapeutics Says It Is Initiating Phase 3 Trial Of AlloNK Plus Rituximab In About 150 Refractory RA Patients In H2 2026; Expects Updated Phase 2a Data From At Least 20 RA Patients In H2 2026

Benzinga Newsdesk www.benzinga.com Positive 72.1%

Neg 0% Neu 0% Pos 72.1%

Comments

No comments yet. Be the first!